Clinicians urged to consider spironolactone in HFPEF despite TOPCAT results
(European Society of Cardiology) Clinicians have been urged to consider using spironolactone in their patients with heart failure and preserved ejection fraction after a post-hoc analysis of the TOPCAT trial showed benefit in patients from the Americas.The research was presented today at the Heart Failure Congress 2014 in Athens, Greece. The Congress is the main annual meeting of the Heart Failure Association of the European Society of Cardiology. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 18, 2014 Category: Global & Universal Source Type: news
Clinicians urged to consider spironolactone in HFPEF despite TOPCAT results
Clinicians have been urged to consider using spironolactone in their patients with heart failure and preserved ejection fraction (HFPEF) after a post-hoc analysis of the TOPCAT trial showed benefit in patients from the Americas. Professor Bertram Pitt said: “We’ve had many studies showing that ACE inhibitors, angiotensin receptor blockers, beta blockers and mineralocorticoid receptor blockers reduce mortality and hospitalisations in patients with heart failure and reduced ejection fraction (HFREF). But no studies have found a benefit of these medications in HFPEF patients.”
...
Source: ESC News and Press - May 14, 2014 Category: Cardiology Source Type: news
TOPCAT reveals regional differences in spironolactone effectiveness for HFpEF
Adding spironolactone to existing treatments does not significantly reduce the composite primary outcome in patients with HF and preserved ejection fraction (HFpEF), reported the phase 3 TOPCAT study.
Topics:
Heart Failure (HF) (Source: ESC News and Press)
Source: ESC News and Press - April 23, 2014 Category: Cardiology Source Type: news
PodMed: A Medical News Roundup From Johns Hopkins (with audio)
(MedPage Today) -- This week's topics include new treatments for hepatitis C, paternal obesity and autism risk, aspirin and preeclampsia, and spironolactone for one form of congestive heart failure. (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - April 11, 2014 Category: Cardiology Source Type: news
TOPCAT in Print, With Quirks: Aldo-Blocker Misses in HFPEFTOPCAT in Print, With Quirks: Aldo-Blocker Misses in HFPEF
Spironolactone didn't show a primary-end-point gain in preserved-ejection-fraction heart failure. But there were glimmers of possible benefit along with a controversy about the trial's design. Heartwire (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - April 10, 2014 Category: Cardiology Tags: Cardiology News Source Type: news
Does Spironolactone Benefit Patients with HF and Preserved Systolic Function? (FREE)
By Harlan M. Krumholz, MD, SM
Spironolactone showed no significant advantage over placebo among patients with heart failure and preserved systolic function in a New England Journal of Medicine study, but the case may not be closed.Some 3500 adults with symptomatic heart failure and a left … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - April 10, 2014 Category: Primary Care Source Type: news
TOPCAT Study Shows Spironolactone Did Not Reduce Primary Outcome, but Did Reduce Hospitalizations for Heart Failure
Spironolactone did not significantly reduce primary endpoint (Source: BWH News)
Source: BWH News - April 10, 2014 Category: Hospital Management Source Type: news
TOPCAT Study Shows Spironolactone Did Not Reduce Primary Outcome, but Did Reduce Hospitalizations for Heart Failure
Spironolactone did not significantly reduce primary endpoint (Source: BWH for Journalists)
Source: BWH for Journalists - April 10, 2014 Category: Research Source Type: news
TOPCAT Study Shows Spironolactone Did Not Reduce Primary Outcome, but Did Reduce Hospitalizations for Heart Failure
Spironolactone did not significantly reduce primary endpoint (Source: BWH News)
Source: BWH News - April 10, 2014 Category: Hospital Management Source Type: news
Spironolactone May Benefit Some HF Patients (CME/CE)
(MedPage Today) -- The TOPCAT trial of spironolactone for patients with heart failure and a preserved ejection fraction failed to meet its primary endpoint, but showed a modest reduction in heart failure hospitalizations with the drug, final results affirmed. (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - April 9, 2014 Category: Cardiology Source Type: news
Troubled NHLBI TOPCAT Trial Disappoints
Although a significant portion of people with heart failure have preserved ejection fraction, none of the proven heart failure therapies has been shown to be beneficial in this important and growing heart failure subpopulation. Now a new NHLBI-funded study has failed to find a benefit in this group for spironolactone, which is a cornerstone of therapy for heart failure patients with reduced ejection fraction. But trial investigators and heart failure experts believe it is too early to dismiss hope that spironolactone and other aldosterone antagonists-- including Pfizer's Inspra (eplerenone)-- may eventually be found to wor...
Source: Forbes.com Healthcare News - April 9, 2014 Category: Pharmaceuticals Authors: Larry Husten Source Type: news
Enhancement of chemotherapy by prevention of tumor cell repair
The body naturally tries to repair lesions in the DNA of tumor cells, and thus reduces the efficacy of chemotherapy. Blocking the mechanisms for DNA repair would help to potentiate chemotherapy by reducing the resistance of cells to treatment. A team of scientists has discovered a new drug that inhibits repair: spironolactone, which seems likely to be used in the very short term as an adjuvant to chemotherapy. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - February 20, 2014 Category: Science Source Type: news
Enhancement of chemotherapy by prevention of tumor cell repair
(INSERM (Institut national de la santé et de la recherche médicale)) The body naturally tries to repair lesions in the DNA of tumour cells, and thus reduces the efficacy of chemotherapy. Blocking the mechanisms for DNA repair would help to potentiate chemotherapy by reducing the resistance of cells to treatment. A team directed by Frédéric Coin, Inserm Research Director in Strasbourg, has discovered a new drug that inhibits repair: spironolactone, which seems likely to be used in the very short term as an adjuvant to chemotherapy. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - February 20, 2014 Category: Biology Source Type: news
14p a day tablet could ease pain for millions of arthritis sufferers without dangerous side effects
Spironolactone, usually used for high blood pressure and heart failure, could help people with osteoarthritis. (Source: the Mail online | Health)
Source: the Mail online | Health - December 16, 2013 Category: Consumer Health News Source Type: news
